What is IMRIS?
Headquartered in Winnipeg, IMRIS Inc. specializes in the design and manufacture of advanced image-guided therapy solutions. Its flagship product, the VISIUS Surgical Theatre, represents a paradigm shift in clinical infrastructure by incorporating magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites. This innovation allows clinicians to access real-time diagnostic data during neurosurgical, spinal, and cardiovascular procedures, thereby enhancing decision-making and patient outcomes. Beyond hardware, the company maintains a robust service model, providing maintenance contracts and specialized disposables that ensure the longevity and operational efficiency of its high-tech surgical environments.
How much funding has IMRIS raised?
IMRIS has raised a total of $67.4M across 2 funding rounds:
Stock Offering
$42.4M
Other Financing Round
$25M
Stock Issuance/Offering (2007): $42.4M, investors not publicly disclosed
Other Financing Round (2013): $25M led by Deerfield
Key Investors in IMRIS
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for IMRIS?
With the support of major enterprise-level financing, IMRIS is well-positioned to expand its global footprint and deepen its penetration into the neurosurgical and cardiovascular markets. The strategic deployment of this capital will likely focus on enhancing the interoperability of the VISIUS platform and accelerating the adoption of its intraoperative imaging suites in tier-one hospital systems. As the demand for precision medicine and minimally invasive surgical techniques continues to rise, IMRIS is poised to leverage its technological moat to maintain its competitive advantage. Future growth will likely be driven by continued investment in R&D and the expansion of its service-based revenue streams, ensuring that the company remains at the forefront of the image-guided therapy landscape.
See full IMRIS company page
